March 8, 2018

Surface Oncology and ProBioGen Sign Second Antibody Manufacturing Program

Berlin, Germany — ProBioGen AG, a premier German service & technology provider for complex therapeutic glycoproteins announced signing the second antibody development project with Cambridge, MA-based Surface Oncology Inc., an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.

Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate. The advantage of this approach is the meticulous analysis of several candidates at the same time while strongly reducing time lines.

Read More

Back to News